Suven Pharmaceuticals Limited, an organization established in November 2018, has transformed into a Wholly Owned Subsidiary of Suven Life Sciences Limited, effective from February 2019. Suven Life Sciences Limited, following the Board meeting on February 5, 2019, declared the demerger of Suven Life Sciences Limited into two parts: Suven Life Sciences Limited, the demerged entity, will persist in pioneering research dedicated to Central Nervous System (CNS) disorders to address significant unmet medical needs worldwide. Suven Pharmaceuticals Limited, the resulting entity, will carry on the CRAMS business operations.
Products & Services
2-(2-ethoxy-phenoxy)ethyl bromide (EPEB)
Country
Suven Life Sciences Ltd
Country
City
Address
2-Bromo-1-2-Ethoxyphenoxy-Ethane
Aciclovir
Acyclovir USP Ph Eur
Sites
Suven Pharmaceuticals Limited
Country
City
Address
Suven Pharmaceuticals Limited
Country
City
Suven Life Science
Address
Suven Life Sciences
Country
City
Suven Life Sciences
Country
City